32 studies on Mots-c curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 4,423 published Mots-c COA source records from third-party laboratories, covering 1,338 publicly attributable vendor identities. Across 4,036 records with positive numeric purity, the arithmetic mean is 99.47%. 8 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 2 positive purity results are below 90%; 100 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-16. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-18, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $8.25 | $7.00–$9.50 | $0.82 | 2 sources · 2 offers |
| 20 mg | $15.75 | $15.50–$16.00 | $0.79 | 2 sources · 2 offers |
| 40 mg | $25.83 | $21.50–$32.50 | $0.65 | 3 sources · 3 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-16. Aggregate calculated: 2026-10-18T04:26:35.128308+00:00. Calculation time is not a laboratory observation date.
Within that total, 1359 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 64 | 99.34% | 0 of 62 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → | |
| #2 | 54 | 99.5% | 0 of 49 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #3 | 27 | 99.42% | 0 of 27 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120376 (99.03%) · #120481 (99.58%) · #120248 (99.79%) · #119652 (99.11%) · #119574 (99.16%) · #119561 (99.2%)
This research suggests that key mitochondrial signaling pathways, as indicated by stable MDP levels, are preserved in individuals with **cerebral palsy**, even in the presence of reduced muscle mass and cardiorespirat…
This research significantly reframes the potential utility of **MOTS-c** in therapeutic applications involving **Mesenchymal Stromal Cells (MSCs)**, particularly in contexts like **obesity** where MSC function is comp…
**MOTS-c could offer a novel therapeutic strategy for mitigating cardiovascular risk in diabetic patients** by directly targeting the `NLRP3` inflammasome, a critical pathway in diabetic cardiomyopathy. This preclinic…
This study highlights **MOTS-c** as a promising biomarker for **Hashimoto's Thyroiditis (HT)**, reflecting the integrated autoimmune and metabolic dysregulation often seen in patients. **Monitoring MOTS-c levels could…
**This comprehensive review provides a critical framework for developing precision therapies against bone aging**, shifting focus from general anti-aging strategies to specific mitochondrial targets. By detailing the …
This review underscores that **targeting mitochondrial health is a critical, underexplored avenue for treating chronic diabetic wounds**, moving beyond symptomatic management to address a root cause of impaired healin…
If this study demonstrates that Ramadan dry fasting elicits a stronger mitophagy response or distinct metabolic benefits compared to standard 16:8 fasting, it could significantly impact our understanding of optimal fa…
This study provides compelling preclinical evidence that **MOTS-c holds therapeutic potential for mitigating skeletal muscle loss in cancer cachexia**, a condition with limited effective treatments. The ability of MOT…
This review significantly advances the understanding of **MOTS-c**'s potential in respiratory medicine, highlighting its dual role as a promising biomarker for disease severity and a therapeutic candidate. **Modulatin…
This study highlights **MOTS-c** as a promising therapeutic candidate for **cardiac ischemia-reperfusion injury**, offering a novel approach to directly target mitochondrial dysfunction. For biohackers and clinicians,…
This review synthesizes evidence on how regular physical exercise mitigates age-related cognitive decline by enhancing mitochondrial biogenesis and efficiency.
This research highlights **Humanin** and **MOTS-c** as promising therapeutic candidates for **atrial fibrillation (AF)**, offering a novel approach beyond current rate and rhythm control strategies. By targeting funda…
This research suggests that **Humanin and MOTS-c offer a novel therapeutic strategy for atrial fibrillation**, by directly targeting the underlying mechanisms of fibrosis and mitochondrial dysfunction, which are often…
Understanding the role of exercise in post-diagnosis breast cancer care is crucial for improving patient outcomes and quality of life. If this pilot study demonstrates positive changes in body composition and identifi…
The ability to accurately predict cardiovascular mortality in Type 2 Diabetes Mellitus patients with Coronary Artery Disease is paramount for enhancing patient care and improving long-term outcomes. Positive findings …
MOTS-c is a novel mitochondrial-derived peptide with potential roles in metabolic regulation, including glucose homeostasis. If this Phase 2a study demonstrates significant improvements in insulin sensitivity and a fa…
This research provides a novel mechanistic understanding of how endurance training improves skeletal muscle mitochondrial function, highlighting MOTS-c as a key player. The findings suggest that circulating MOTS-c lev…
These findings are highly significant as they identify MOTS-c as a critical regulator of pancreatic islet cell senescence, a process implicated in both type 1 and type 2 diabetes. The ability of MOTS-c to reduce senes…
This research highlights MOTS-c as a promising therapeutic candidate for osteoarthritis, offering a novel approach by simultaneously targeting mitochondrial health, reducing inflammatory cell death, and activating pro…
This review highlights a significant untapped area of research with profound implications for understanding and treating lung diseases. Given the established roles of MDPs in other complex diseases, their investigatio…
This detailed chemical profile is crucial for the unambiguous identification and characterization of MOTS-c in research and development. Accurate chemical identification is the bedrock for all subsequent experimental …
This comprehensive screening program holds immense potential to revolutionize early intervention strategies for newborn hearing loss. By identifying genetic causes early, clinicians can offer more personalized prognos…
Free, no account — handy when you're working with Mots-c.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account